Tokyo, Feb 15, 2013 (JCN) - Daiichi Sankyo will collaborate with a new company, Orphan Disease Treatment Institute, in the development of a treatment for Duchenne muscular dystrophy (DMD) with the active ingredient ENA oligonucleotide, a modified nucleic acid made using proprietary technology owned by Daiichi Sankyo.
Daiichi Sankyo is establishing the new company with Innovation Network Corporation of Japan (INCJ) and Mitsubishi UFJ Capital Co., Ltd. (MUC). INCJ will underwrite third party allocation of new shares for the new company with a maximum investment of 1.65 billion yen. The new company will also issue new shares by third party allocation for a fund managed by MUC.
Daiichi Sankyo will invest in the new company and mainly conduct development with the goal of achieving proof of concept (POC) for clinical drug development.
In 2006, professor Masafumi Matsuo (Kobe Gakuin University Department of Medical Rehabilitation) and designated professor Yasuhiro Takeshima (Kobe University Graduate School of Medicine Department of Pediatrics) were the first in the world to demonstrate the effectiveness of anti-sense oligonucleotides to restore dystrophin expression in DMD sufferers through the mechanism known as exon skipping.
Daiichi Sankyo and Orphan Disease Treatment Institute will jointly conduct clinical and non-clinical studies with the cooperation and support of these two professors with the aim of achieving POC.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy
(Feb 15, 2013)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign
(Dec 20, 2012)
|
|
|
Daiichi Sankyo, Ranbaxy Launch Psteoporosis Medication EVISTA in Romania
(Sept 2, 2009)
|
|
|
Daiichi Sankyo Files Application for Dysuria Treatment KMD-3213 in China
(Jan 8, 2009)
|
|
|
Daiichi Sankyo and Ranbaxy Move Forward Toward The Completion of the Landmark Deal
(Oct 20, 2008)
|
|
|
Daiichi Sankyo's Tender Offer for Ranbaxy Ends in Success
(Oct 17, 2008)
|
|
|
Shionogi to Acquire U.S. Drug Maker Sciele Pharma
(Sept 1, 2008)
|
|
|
Daiichi Sankyo to Buy Indian Drug Giant Ranbaxy
(June 11, 2008)
|
|
|
Daiichi Sankyo to Acquire German Biomedical Firm
(May 21, 2008)
|
|
|
Daiichi Sankyo Launches Sales Unit in Turkey
(May 13, 2008)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Drugs & OTC news...
|
|
